HGF/c-Met Axis: The Advanced Development in Digestive System Cancer

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• The hepatocyte growth factor (HGF)/c-Met signaling pathway is frequently dysregulated in digestive system cancers.
• Abnormal HGF/c-Met activation promotes tumor cell proliferation, invasion, and metastasis.
• Overexpression of c-Met correlates with poor prognosis in digestive cancer patients, identifying it as a therapeutic target.

Purpose of the Study:

• To review the current clinical research on HGF/c-Met pathway inhibitors for digestive system cancers.
• To summarize the development of anti-HGF/c-Met antibodies and small-molecule c-Met inhibitors.
• To propose future research directions for this therapeutic axis.

Main Methods:

• Comprehensive literature search of preclinical and clinical studies on HGF/c-Met inhibitors in digestive cancers.
• Analysis of clinical trial data for HGF/c-Met targeted therapies.
• Review of ongoing research and development in antibody and small-molecule inhibitor strategies.

Main Results:

• Despite extensive research, significant clinical success for anti-HGF/c-Met treatments in digestive cancers remains limited.
• Various antibodies and small-molecule inhibitors targeting the HGF/c-Met axis have been developed and tested.
• Challenges in efficacy and patient selection persist in current clinical trials.

Conclusions:

• The HGF/c-Met axis remains a critical target for digestive system cancers.
• Further research is needed to overcome therapeutic limitations and improve patient outcomes.
• Optimizing inhibitor strategies and identifying predictive biomarkers are crucial for future success.